TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7947312

Group type: EXPERIMENTAL
Intervention: Contralateral placement of the ventricular catheter
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ipsilateral placement of the ventricular catheter
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Special catheter with two sets of holes (contralateral placement)
Number of subjects: 58
Study: 3145528

Group type: EXPERIMENTAL
Intervention: Amphetamine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control) administration
Number of subjects: 0
Study: 31022003

Group type: EXPERIMENTAL
Intervention: Clinic-based and home-based exercise intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 25
Study: 29073915

Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Bag-valve-mask (BVM)
Number of subjects: 78
Study: 26092818

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily) plus trastuzumab and paclitaxel
Number of subjects: 719

Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg once daily)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 719
Study: 23750464

Group type: EXPERIMENTAL
Intervention: In-person brief motivational enhancement intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Assessment control group
Number of subjects: 212
Study: 21276316

Group type: EXPERIMENTAL
Intervention: TBA Care secretion detector
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard indications for suctioning (control group)
Number of subjects: 72
Study: 19775455

Group type: EXPERIMENTAL
Intervention: Outreach motivational interviewing (MI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 302
Study: 16675379

Group type: EXPERIMENTAL
Intervention: Teen Club plus PALS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Teen Club
Number of subjects: 16
Study: 15093800

Group type: EXPERIMENTAL
Intervention: Youth-friendly intervention program providing awareness, counseling, and services related to sexuality and reproduction.
Number of subjects: 2227

Group type: COMPARATOR
Intervention: Control site with routine program activities only.
Number of subjects: 2227

Group type: EXPERIMENTAL
Intervention: Intervention group participants at onset of sexual intercourse.
Number of subjects: 2227
Study: 11252074

Group type: EXPERIMENTAL
Intervention: Active nasal dilator strip
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9285305

Group type: EXPERIMENTAL
Intervention: 5 alpha-reductase inhibitor (finasteride 5 mg/day)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 7687111

Group type: EXPERIMENTAL
Intervention: PRP-OMPC vaccine
Number of subjects: 124
Study: 3828185

Group type: EXPERIMENTAL
Intervention: Extradural phenoperidine 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extradural diamorphine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.m. diamorphine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extradural groups (phenoperidine and diamorphine)
Number of subjects: 0
Study: 31725196

Group type: EXPERIMENTAL
Intervention: Palonosetron plus aprepitant
Number of subjects: 130

Group type: COMPARATOR
Intervention: Palonosetron alone
Number of subjects: 130
Study: 31006399

Group type: EXPERIMENTAL
Intervention: POCUS group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Feeding group (standard procedure)
Number of subjects: 201
Study: 29185403

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional phacoemulsification
Number of subjects: 50
Study: 26236130

Group type: EXPERIMENTAL
Intervention: Combined treatment group (DFDBA and barrier membrane)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined treatment + doxycycline group (DFDBA and barrier membrane with local doxycycline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (DFDBA and barrier membrane without doxycycline)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Doxycycline group (DFDBA and barrier membrane with doxycycline)
Number of subjects: 24
Study: 23332533

Group type: EXPERIMENTAL
Intervention: Self-monitoring (SM) intervention, daily dietary logs for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Attention-control (AC) condition
Number of subjects: 40
Study: 21700946

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) - 4 individual, weekly sessions
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual stroke care (Control)
Number of subjects: 411
Study: 19625862

Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (up to 7 sessions over 9 months)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (for those more depressed at baseline)
Number of subjects: 171
Study: 16703253

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (5 mW HeNe laser on 22 acupuncture points for 15 s each) plus cervical collar and a combination of paracetamol and chlormezanone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo laser treatment plus cervical collar and a combination of paracetamol and chlormezanone
Number of subjects: 45
Study: 15319718

Group type: EXPERIMENTAL
Intervention: Oxandrolone (10 mg po BID)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 41
Study: 11680441

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 9648764

Group type: EXPERIMENTAL
Intervention: 14-gauge biopsy needle
Number of subjects: 64

Group type: COMPARATOR
Intervention: 16-gauge biopsy needle
Number of subjects: 64

Group type: COMPARATOR
Intervention: 18-gauge biopsy needle
Number of subjects: 64
Study: 7853450

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 48

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lower limb pain tolerance
Number of subjects: 48
Study: 2524203

Group type: EXPERIMENTAL
Intervention: Thyroid hormone supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 73912

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (P.G.A.) suture material
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Silk suture material
Number of subjects: 1000
Study: 29362258

Group type: EXPERIMENTAL
Intervention: FreeO2 technology
Number of subjects: 47

Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 47
Study: 30261837

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine sprayed on the tracheal mucosa, epiglottis, tongue base, and glottis
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54
Study: 28703316

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 36
Study: 26569658

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 12 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir plus Ribavirin for 12 weeks
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir for 24 weeks
Number of subjects: 267

Group type: COMPARATOR
Intervention: Ribavirin (in combination with Sofosbuvir and Velpatasvir)
Number of subjects: 267

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 267
Study: 23593314

Group type: EXPERIMENTAL
Intervention: Tipranavir-Ritonavir based regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darunavir-Ritonavir based regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tipranavir-Ritonavir or Darunavir-Ritonavir based regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator selected boosted comparator HIV-1 protease inhibitors (CPI-Ritonavir)
Number of subjects: 0
Study: 21037482

Group type: EXPERIMENTAL
Intervention: Tailored cardiac rehabilitation program with motivational interviewing
Number of subjects: 225

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 225
Study: 18280961

Group type: EXPERIMENTAL
Intervention: Mini-flap procedure
Number of subjects: 129

Group type: COMPARATOR
Intervention: Flap procedure
Number of subjects: 129
Study: 16920858

Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg daily for 6 months)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily for 6 months)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Both iron and zinc supplementation
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 12943174

Group type: EXPERIMENTAL
Intervention: Kyuki‐chouketsu‐in at a dose of 6.0 g/day (Group K)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ergometrine (methylergometrine maleate) at a dose of 0.375 mg/day (Group E)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Kyuki‐chouketsu‐in (Group K)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ergometrine (Group E)
Number of subjects: 171
Study: 10848853

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10^6 units bolus, followed by 0.5 x 10^6 units infusion every 30 min)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 77
Study: 9332684

Group type: EXPERIMENTAL
Intervention: High-dose MTX
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Moderate-dose MTX
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Chemotherapy with MTX and CDP
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Relapse-free interval longer than 24 months
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Relapse-free interval shorter than 24 months
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Patients not surgically treated
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Good histologic response
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: LDH baseline value within normal range
Number of subjects: 127
Study: 12959279

Group type: EXPERIMENTAL
Intervention: Combination of enalapril and doxazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 12
Study: 2433701

Group type: EXPERIMENTAL
Intervention: Griseofulvin, 125 mg four times daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methisoprinol, 1 g four times daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Griseofulvin plus methisoprinol (dosage schedules as above)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo, four times daily
Number of subjects: 57
Study: 30044846

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 466

Group type: COMPARATOR
Intervention: Standard care (no fibrin sealant)
Number of subjects: 466
Study: 26271769

Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 120 min prior to and during exercise (2HEX)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 120 min prior to and during exercise (2HEX)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 60 min prior to and during exercise (1HEX)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 60 min prior to and during exercise (1HEX)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bright Light (BL, 4420 lx) for 60 min prior to exercise (1H)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Moderate Light (ML, 230 lx) for 60 min prior to exercise (1H)
Number of subjects: 41
Study: 24329943

Group type: EXPERIMENTAL
Intervention: Educational intervention based on health locus of control
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 230
Study: 24260184

Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (20 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 32
Study: 21440994

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 75
Study: 19032133

Group type: EXPERIMENTAL
Intervention: tolterodine ER (4 mg)
Number of subjects: 617

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 617
Study: 16368313

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Composite outcome (death, myocardial infarction, target vessel revascularization, or bailout glycoprotein IIb/IIIa)
Number of subjects: 100
Study: 14629657

Group type: EXPERIMENTAL
Intervention: Conference abstracts from the Thoracic Society of Australia and New Zealand
Number of subjects: 9691
Study: 10979921

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study: 8810694

Group type: EXPERIMENTAL
Intervention: 20 degree flexion axial radiography (AR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Computerized tomography (CT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quadriceps muscle contraction
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 20 degrees AR
Number of subjects: 31
Study: 1358231

Group type: EXPERIMENTAL
Intervention: 7 mg muscimol (GABA agonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2951501

Group type: EXPERIMENTAL
Intervention: SR 270258 (2 mg/m2, subcutaneous injections, three times per week for 1 month)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 16
Study: 31004243

Group type: EXPERIMENTAL
Intervention: Internet behavioral weight loss program (WT LOSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Internet education control (CONTROL)
Number of subjects: 40
Study: 29783041

Group type: EXPERIMENTAL
Intervention: Randomized response technique (RRT) combined with network scale-up method (NSUM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Network scale-up method (NSUM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiplier method
Number of subjects: 0
Study: 25939797

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for 4 weeks
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo treatment for 4 weeks
Number of subjects: 141
Study: 25552610

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22034637

Group type: EXPERIMENTAL
Intervention: Pyridorin 150 mg twice daily
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pyridorin 300 mg twice daily
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 20447477

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 3
Study: 18484199

Group type: EXPERIMENTAL
Intervention: Chitosan 0.1%
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sodium hyaluronate 1.4%
Number of subjects: 140
Study: 16843455

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: metformin (1 g twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 31
Study: 12802025

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (24 Gy to involved nodal areas, 16 to 24 Gy to extranodal sites)
Number of subjects: 421

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (30 Gy to nodal areas, 18 to 24 Gy to extranodal sites)
Number of subjects: 421
Study: 10427138

Group type: EXPERIMENTAL
Intervention: p53 mutation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CDKN2A mutation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PTEN mutation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: p53 genetic status
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CDKN2A and PTEN alterations
Number of subjects: 135
Study: 7770983

Group type: EXPERIMENTAL
Intervention: Two-sphere plug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: One-sphere plug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preference plug (either two-sphere or one-sphere)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two-sphere device
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Urinary tract infections
Number of subjects: 40
Study: 2272291

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (PST)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 340006

Group type: EXPERIMENTAL
Intervention: Indoprofen 800 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31810854

Group type: EXPERIMENTAL
Intervention: Verum TTNS
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham TTNS
Number of subjects: 9
Study: 30779616

Group type: EXPERIMENTAL
Intervention: Integrated binocular stimulation mode with low temporal frequency
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Integrated binocular stimulation mode with high temporal frequency
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Contrast balance adjusted in horizontal state
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Contrast balance adjusted in vertical state
Number of subjects: 97
Study: 26406911

Group type: EXPERIMENTAL
Intervention: High carbohydrate nutritional intervention (HCHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate carbohydrate nutritional intervention (CON)
Number of subjects: 13
Study: 26180251

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 33665

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 33665
Study: 23835717

Group type: EXPERIMENTAL
Intervention: 3D‐CRT APBI (38.5 Gy in 10 fractions twice daily)
Number of subjects: 2135

Group type: COMPARATOR
Intervention: WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation)
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: 3D‐CRT APBI
Number of subjects: 2135

Group type: COMPARATOR
Intervention: WBI
Number of subjects: 2135
Study: 22214113

Group type: EXPERIMENTAL
Intervention: Weighted vest
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-weighted vest (Control)
Number of subjects: 10
Study: 19193900

Group type: EXPERIMENTAL
Intervention: D(2) receptor agonist bromocriptine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug administration)
Number of subjects: 0
Study: 16960939

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1) for patients with FA-SSc
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT) at Time 1 (T1) for patients with isolated ground-glass opacities
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with abnormal HRCT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Normal initial HRCT
Number of subjects: 90
Study: 15343191

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg daily
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Amlodipine (dose > or = 0.06 mg/kg per day)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 268
Study: 10943966

Group type: EXPERIMENTAL
Intervention: Lang II Random Dot Stereotest
Number of subjects: 4293
Study: 9301693

Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRH‐A
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRH‐A
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Bicalutamide plus LHRH‐A
Number of subjects: 813

Group type: COMPARATOR
Intervention: Flutamide plus LHRH‐A
Number of subjects: 813
Study: 8359186

Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.5% solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo solution (mannitol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibopamine 1% solution
Number of subjects: 20
Study: 3734450

Group type: EXPERIMENTAL
Intervention: Low-salt diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 0
Study: 29864710

Group type: EXPERIMENTAL
Intervention: High force mobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medium force mobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low force mobilization
Number of subjects: 60
Study: 27107634

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN) via nasojejunal tube initiated within 24 hours of admission
Number of subjects: 214

Group type: COMPARATOR
Intervention: Nil-by-mouth (NBM) regimen
Number of subjects: 214
Study: 24561970

Group type: EXPERIMENTAL
Intervention: 30 g/day IV glutamine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 30 g/day enteral glutamine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 15 g/day IV and 15 g/day enteral glutamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Only enteral feeding (control group)
Number of subjects: 120
Study: 23678503

Group type: EXPERIMENTAL
Intervention: Therapeutic education programme (three-day intervention)
Number of subjects: 120
Study: 21122202

Group type: EXPERIMENTAL
Intervention: rhBNP
Number of subjects: 126
Study: 17452062

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Donepezil and Control)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: MRI measures
Number of subjects: 131